Leyla Demir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Leyla Demir has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Saliha Aksun
İzmir Katip Çelebi Üniversitesi
5 shared publications - Mert Üğe
Karabuk Public Health Laboratory
3 shared publications - Tuğba Öncel Van
Department of Medical Biochemistry, Gazi State Hospital, Samsun, Türkiye
3 shared publications - Mehmet Eren Kalender
Department of Medical Oncology Atatürk Training and Research Hospital İzmir Katip Çelebi University İzmir Türkiye
2 shared publications - Utku Oflazoglu
İzmir Katip Çelebi Üniversitesi Atatürk Eğitim ve Araştırma Hastanesi
2 shared publications - Zeynep Gülsüm Güç
Department of Medical Oncology Atatürk Training and Research Hospital İzmir Katip Çelebi University İzmir Türkiye
2 shared publications
Latest Publications
- Open Access
- 25 August 2026
- Published by Wiley in Psycho-Oncology
- Vol. 35 (8) , e70590
Neurotrophic–Inflammatory Imbalance and Cognitive Decline After Adjuvant Chemotherapy in Colon Cancer: A Prospective Cohort Study
Background: Cancer‐related cognitive impairment (CRCI) is a prevalent yet underrecognized complication among colon cancer survivors that adversely affects quality of life and psychological well‐being. Emerging evidence suggests that neurotrophic dysregulation and systemic inflammation may contribute to chemotherapy‐related neurotoxicity; however, longitudinal biomarker‐based data remain limited. Methods: In this prospective cohort study, 127 patients with resected colon cancer were evaluated at baseline and at the 6‐month follow‐up. Of these, 83 received adjuvant chemotherapy and 44 underwent postoperative surveillance alone. Cognitive performance (MoCA), depressive symptoms (HADS‐D), and peripheral neuropathy (CIPN20) were assessed alongside serum brain‐derived neurotrophic factor (BDNF) levels and systemic inflammatory markers, including neutrophil‐to‐lymphocyte ratio (NLR) and C‐reactive protein‐to‐albumin ratio (CAR). Linear mixed model and logistic regression analyses were performed to identify factors associated with cognitive decline. Results: Adjuvant chemotherapy was associated with significant reductions in MoCA scores and serum BDNF levels (both p < 0.001), particularly among patients receiving the oxaliplatin‐based XELOX regimen. Greater longitudinal reductions in BDNF (ΔBDNF) were independently associated with higher odds of CRCI (OR = 0.749 per 10 ng/mL increase in ΔBDNF, 95% CI: 0.658–0.854, p < 0.001). The model including ΔBDNF showed higher apparent discrimination than the corresponding model without ΔBDNF (AUC = 0.929 vs. 0.812). Conclusion: Longitudinal reductions in serum BDNF were independently associated with CRCI among patients receiving adjuvant chemotherapy. These findings support a potential role for neurotrophic dysregulation in chemotherapy‐related cognitive decline and highlight the need for further validation studies evaluating BDNF as a candidate biomarker for CRCI.
- 25 August 2026
- Published by Wiley in Psycho-Oncology
- Vol. 35 (8) , e70590
Open AccessNeurotrophic–Inflammatory Imbalance and Cognitive Decline After Adjuvant Chemotherapy in Colon Cancer: A Prospective Cohort Study
Background: Cancer‐related cognitive impairment (CRCI) is a prevalent yet underrecognized complication among colon cancer survivors that adversely affects quality of life and psychological well‐being. Emerging evidence suggests that neurotrophic dysregulation and systemic inflammation may contribute to chemotherapy‐related neurotoxicity; however, longitudinal biomarker‐based data remain limited. Methods: In this prospective cohort study, 127 patients with resected colon cancer were evaluated at baseline and at the 6‐month follow‐up. Of these, 83 received adjuvant chemotherapy and 44 underwent postoperative surveillance alone. Cognitive performance (MoCA), depressive symptoms (HADS‐D), and peripheral neuropathy (CIPN20) were assessed alongside serum brain‐derived neurotrophic factor (BDNF) levels and systemic inflammatory markers, including neutrophil‐to‐lymphocyte ratio (NLR) and C‐reactive protein‐to‐albumin ratio (CAR). Linear mixed model and logistic regression analyses were performed to identify factors associated with cognitive decline. Results: Adjuvant chemotherapy was associated with significant reductions in MoCA scores and serum BDNF levels (both p < 0.001), particularly among patients receiving the oxaliplatin‐based XELOX regimen. Greater longitudinal reductions in BDNF (ΔBDNF) were independently associated with higher odds of CRCI (OR = 0.749 per 10 ng/mL increase in ΔBDNF, 95% CI: 0.658–0.854, p < 0.001). The model including ΔBDNF showed higher apparent discrimination than the corresponding model without ΔBDNF (AUC = 0.929 vs. 0.812). Conclusion: Longitudinal reductions in serum BDNF were independently associated with CRCI among patients receiving adjuvant chemotherapy. These findings support a potential role for neurotrophic dysregulation in chemotherapy‐related cognitive decline and highlight the need for further validation studies evaluating BDNF as a candidate biomarker for CRCI.
- 30 December 2024
- Published by Caleo in Turkish Society of Clinical Biochemistry
- Vol. 22 (3) , 113-124
Investigation Bisphenol A and Phthalate Levels in Idiopathic Hyperandrogenemia
Amaç: İdiyopatik hiperandrojenemi, kadınlarda hirsutizm belirtileri, artmış serum androjen düzeyleri, normal adet döngüsü ve normal yumurtalık morfolojisi ile seyreden bir hastalık olarak tanımlanır. Bu çalışmada, Bisfenol A ve mono-etilhekzil fitalat'ın bu hastalıkla ilişkisinin incelenmesi amaçlandı. Materyal ve Metod: Araştırmaya 18-45 yaş arası toplam 91 birey dahil edildi. Hasta grubunu, endokrin polikliniğine hirsutizm bulgusu ile başvuran ve androjen düzeyi yüksek olan 43 kadın; kontrol grubunu ise hirsutizm bulgusu ve herhangi bir ek hastalığı olmayan 48 sağlıklı kadın oluşturdu. Bisfenol A ve mono-etilhekzil fitalat düzeyleri idrarda sıvı kromatografi-kütle spektrometri yöntemiyle ölçüldü. Bulgular: Hasta grubunda idrar Bisfenol A düzeyleri, kontrol grubuna göre anlamlı olarak yüksek bulundu (1,6 ng/ml; 0,55 ng/ml, p=0,035). Mono-etilhekzil fitalat düzeyleri ise kontrol grubunda, hasta grubuna göre anlamlı olarak yüksek bulundu (1,81 ng/ml; 1,66 ng/ml, p=0,01). Lojistik regresyon analizinde odds oranları, BPA için 1,91 (%95 güven aralığı: 1,13-3,24; p<0,05), yaş için 0,91 (%95 güven aralığı: 0,81-1,01; p=0,09), fT3 için 18,74 (%95 güven aralığı: 3,86-90,85; p<0,05), prolaktin için 1,06 (%95 güven aralığı: 0,98-1,14; p=0,09) olarak bulundu. Sonuç: Hiperandrojenemi etiyolojisinde daha az sıklıkla yer alan bu grupta, endokrin bozucu kimyasalların etkisinin incelenmesi çalışmamızı özgün kılmaktadır. Hasta grubunda Bisfenol A idrar düzeyinin kontrol grubuna göre yüksek olması, idiyopatik hiperandrojenemililerde Bisfenol A'nın etkisini düşündürmektedir. Kontrol grubunda ise mono-etilhekzil fitalat düzeylerinin daha yüksek bulunması, daha fazla ftalat metabolitinin incelenmesi ve daha fazla çalışma yapılması gerektiğini düşündürmektedir.
- 30 December 2024
- Published by Caleo in Turkish Society of Clinical Biochemistry
- Vol. 22 (3) , 113-124
Investigation Bisphenol A and Phthalate Levels in Idiopathic Hyperandrogenemia
Amaç: İdiyopatik hiperandrojenemi, kadınlarda hirsutizm belirtileri, artmış serum androjen düzeyleri, normal adet döngüsü ve normal yumurtalık morfolojisi ile seyreden bir hastalık olarak tanımlanır. Bu çalışmada, Bisfenol A ve mono-etilhekzil fitalat'ın bu hastalıkla ilişkisinin incelenmesi amaçlandı. Materyal ve Metod: Araştırmaya 18-45 yaş arası toplam 91 birey dahil edildi. Hasta grubunu, endokrin polikliniğine hirsutizm bulgusu ile başvuran ve androjen düzeyi yüksek olan 43 kadın; kontrol grubunu ise hirsutizm bulgusu ve herhangi bir ek hastalığı olmayan 48 sağlıklı kadın oluşturdu. Bisfenol A ve mono-etilhekzil fitalat düzeyleri idrarda sıvı kromatografi-kütle spektrometri yöntemiyle ölçüldü. Bulgular: Hasta grubunda idrar Bisfenol A düzeyleri, kontrol grubuna göre anlamlı olarak yüksek bulundu (1,6 ng/ml; 0,55 ng/ml, p=0,035). Mono-etilhekzil fitalat düzeyleri ise kontrol grubunda, hasta grubuna göre anlamlı olarak yüksek bulundu (1,81 ng/ml; 1,66 ng/ml, p=0,01). Lojistik regresyon analizinde odds oranları, BPA için 1,91 (%95 güven aralığı: 1,13-3,24; p<0,05), yaş için 0,91 (%95 güven aralığı: 0,81-1,01; p=0,09), fT3 için 18,74 (%95 güven aralığı: 3,86-90,85; p<0,05), prolaktin için 1,06 (%95 güven aralığı: 0,98-1,14; p=0,09) olarak bulundu. Sonuç: Hiperandrojenemi etiyolojisinde daha az sıklıkla yer alan bu grupta, endokrin bozucu kimyasalların etkisinin incelenmesi çalışmamızı özgün kılmaktadır. Hasta grubunda Bisfenol A idrar düzeyinin kontrol grubuna göre yüksek olması, idiyopatik hiperandrojenemililerde Bisfenol A'nın etkisini düşündürmektedir. Kontrol grubunda ise mono-etilhekzil fitalat düzeylerinin daha yüksek bulunması, daha fazla ftalat metabolitinin incelenmesi ve daha fazla çalışma yapılması gerektiğini düşündürmektedir.
- 20 September 2023
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 31 (10) , 1-11
The relationship between sarcopenia and serum irisin and TNF-α levels in newly diagnosed cancer patients
Objective Sarcopenia in patients with cancer makes patients physically weak and adversely affects their compliance with treatment. In this study, we investigated the relationship between sarcopenia in patients with cancer and circulating irisin and tumor necrosis factor-alpha (TNF-α) levels. Material and method A total of 141 patients with different types of newly diagnosed cancer were divided into two groups, sarcopenia (n = 72) and non-sarcopenia (n = 69) groups. The body compositions of the patients were measured using bioelectrical impedance (BIA) and muscle strength using hand grip strength (HGS) tests. Serum irisin and TNF-α levels were measured using an enzyme-linked immunosorbent assay. Results In our study, serum irisin levels were found to be significantly lower (p < 0.01) and TNF-α levels were found to be significantly higher (p = 0.014) in the sarcopenia group. Skeletal muscle index (SMI) and HGS values and serum irisin levels were positively correlated [(r: 0.451, p < 0.001), (r: 0.469, p < 0.001)], and SMI and HGS values and serum TNF-α levels were negatively correlated [(r: -0.181, p = 0.032) and (r: -0.143, p = 0.090), respectively]. In addition, multiple linear regression analysis showed that serum irisin and TNF-α levels were independent predictors of sarcopenia. Conclusion Serum irisin levels were found to be significantly lower in patients with cancer with sarcopenia, and TNF-α levels were found to be significantly higher. These two markers can be used as potential biomarkers for the diagnosis of sarcopenia in patients with cancer. The efficacy and possible mechanisms of action of irisin and TNF-α in the diagnosis of sarcopenia should be investigated with larger patient groups.
- 20 September 2023
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 31 (10) , 1-11
The relationship between sarcopenia and serum irisin and TNF-α levels in newly diagnosed cancer patients
Objective Sarcopenia in patients with cancer makes patients physically weak and adversely affects their compliance with treatment. In this study, we investigated the relationship between sarcopenia in patients with cancer and circulating irisin and tumor necrosis factor-alpha (TNF-α) levels. Material and method A total of 141 patients with different types of newly diagnosed cancer were divided into two groups, sarcopenia (n = 72) and non-sarcopenia (n = 69) groups. The body compositions of the patients were measured using bioelectrical impedance (BIA) and muscle strength using hand grip strength (HGS) tests. Serum irisin and TNF-α levels were measured using an enzyme-linked immunosorbent assay. Results In our study, serum irisin levels were found to be significantly lower (p < 0.01) and TNF-α levels were found to be significantly higher (p = 0.014) in the sarcopenia group. Skeletal muscle index (SMI) and HGS values and serum irisin levels were positively correlated [(r: 0.451, p < 0.001), (r: 0.469, p < 0.001)], and SMI and HGS values and serum TNF-α levels were negatively correlated [(r: -0.181, p = 0.032) and (r: -0.143, p = 0.090), respectively]. In addition, multiple linear regression analysis showed that serum irisin and TNF-α levels were independent predictors of sarcopenia. Conclusion Serum irisin levels were found to be significantly lower in patients with cancer with sarcopenia, and TNF-α levels were found to be significantly higher. These two markers can be used as potential biomarkers for the diagnosis of sarcopenia in patients with cancer. The efficacy and possible mechanisms of action of irisin and TNF-α in the diagnosis of sarcopenia should be investigated with larger patient groups.
- 25 August 2023
- Published by Caleo in Turkish Society of Clinical Biochemistry
- Vol. 21 (2) , 094-101
Laboratuvarımızda Çalışılan Prenatal Tarama Testlerinde Ölçüm Belirsizliği
Amaç: Ölçüm belirsizliği hem bir yöntemin amaca uygunluğu hem de bir laboratuvarda elde edilen analitik sonuçların güvenilirliği için önemli bir göstergedir. ISO 15189 gibi akreditasyon süreçleri de laboratuvarlardan ölçüm belirsizliği için belirlenmiş bir yöntemleri olmasını ve istendiğinde ölçüm belirsizliği sonuçlarını sağlamasını beklemektedir. Bu çalışmada amacımız birinci ve ikinci trimester prenatal tarama testlerinde kullanılan biyokimya parametrelerinin ölçüm belirsizliğini hesaplayıp bu değerleri total izin verilebilir hata oranları ile karşılaştırmaktır. Gereç ve Yöntem: Laboratuvarımızda prenatal tarama testlerinde kullanılan gebelikle ilişkili plazma protein-A (PAPP-A), serbest beta insan koryonik gonadotropini (sß-hCG), alfa feto protein (AFP), insan koryonik gonadotropini (HCG) ve unkonjuge estriol (uE3) parametreleri için ölçüm belirsizliği hesaplandı, Nordest kılavuzunda yer alan Avrupa akreditasyon rehberi ve Eurolab teknik raporu ISO 21748 rehberinden faydalanarak hesaplamalar yapıldı. Bu hesaplamalarda iç kalite kontrol ve dış kalite kontrol sonuçları kullanıldı. Bulgular: Ölçüm belirsizlik değerleri AFP için %16.4, sβ-hCG için %17.04, HCG için %27.84, PAPP-A için %18.54 ve uE3 için %22.52 olarak bulundu. Çalışmamızda en yüksek ölçüm belirsizliği HCG ve uE3 parametreleri için bulunurken en düşük ölçüm belirsizliği ise AFP için bulundu. Sonuç: Laboratuvarımızda prenatal tarama testlerine ait biyokimyasal parametrelerin ölçüm belirsizlikleri hesaplanmıştır. HCG, PAPP-A ve uE3 testlerinin ölçüm belirsizliği yüksek bulunmuştur, Özellikle risk açısından eşik değere yakın prenatal tarama testlerinde ölçüm belirsizliğinin dikkate alınarak sonuçların yorumlanması önemlidir.
- 25 August 2023
- Published by Caleo in Turkish Society of Clinical Biochemistry
- Vol. 21 (2) , 094-101
Laboratuvarımızda Çalışılan Prenatal Tarama Testlerinde Ölçüm Belirsizliği
Amaç: Ölçüm belirsizliği hem bir yöntemin amaca uygunluğu hem de bir laboratuvarda elde edilen analitik sonuçların güvenilirliği için önemli bir göstergedir. ISO 15189 gibi akreditasyon süreçleri de laboratuvarlardan ölçüm belirsizliği için belirlenmiş bir yöntemleri olmasını ve istendiğinde ölçüm belirsizliği sonuçlarını sağlamasını beklemektedir. Bu çalışmada amacımız birinci ve ikinci trimester prenatal tarama testlerinde kullanılan biyokimya parametrelerinin ölçüm belirsizliğini hesaplayıp bu değerleri total izin verilebilir hata oranları ile karşılaştırmaktır. Gereç ve Yöntem: Laboratuvarımızda prenatal tarama testlerinde kullanılan gebelikle ilişkili plazma protein-A (PAPP-A), serbest beta insan koryonik gonadotropini (sß-hCG), alfa feto protein (AFP), insan koryonik gonadotropini (HCG) ve unkonjuge estriol (uE3) parametreleri için ölçüm belirsizliği hesaplandı, Nordest kılavuzunda yer alan Avrupa akreditasyon rehberi ve Eurolab teknik raporu ISO 21748 rehberinden faydalanarak hesaplamalar yapıldı. Bu hesaplamalarda iç kalite kontrol ve dış kalite kontrol sonuçları kullanıldı. Bulgular: Ölçüm belirsizlik değerleri AFP için %16.4, sβ-hCG için %17.04, HCG için %27.84, PAPP-A için %18.54 ve uE3 için %22.52 olarak bulundu. Çalışmamızda en yüksek ölçüm belirsizliği HCG ve uE3 parametreleri için bulunurken en düşük ölçüm belirsizliği ise AFP için bulundu. Sonuç: Laboratuvarımızda prenatal tarama testlerine ait biyokimyasal parametrelerin ölçüm belirsizlikleri hesaplanmıştır. HCG, PAPP-A ve uE3 testlerinin ölçüm belirsizliği yüksek bulunmuştur, Özellikle risk açısından eşik değere yakın prenatal tarama testlerinde ölçüm belirsizliğinin dikkate alınarak sonuçların yorumlanması önemlidir.
- 7 February 2023
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 83 (2) , 125-132
Presence of macroproteins on the measurement of vitamin B12: studying high vitamin B12 levels using polyethylene glycol and heterophile antibody blocking tubes
Immune methods are measurement systems that can be affected by interference. The interfering substance may be endogenous immunoglobulins, antibodies, analyte-antibody complexes, and heterophile antibodies. In our study, we aimed to investigate the effect of macrovitamin B12 on high vitamin B12 levels measured using immune methods. Among the serum samples studied in our laboratory; serum from 145 individuals was determined as the patient group and serum from 50 individuals was determined as the control group. We investigated the effect of macroprotein on B12 measurement by using polyethylene glycol (PEG) precipitation, heterophile antibody blocking tube (HBT) and serial dilution methods. According to the recovery evaluation and the modified reference range evaluation after precipitation with PEG, the macrovitamin B12 percentage in the patient group was 58 (40%) and 65 (44.8%), respectively. There was no decrease in vitamin B12 values after the study with HBT. A lack of linearity was observed in 23 (18.7%) of 123 sera with serial dilution method. Macrovitamin B12 should be considered as a differential diagnosis of unexpectedly high vitamin B12 levels. According to the results of our study, we think that it would be appropriate to precipitate with PEG first when there is a suspicion of macrovitamin B12. In collaboration with clinical and laboratory, we recommend that the patient’s clinical status and additional laboratory findings be examined, and the patient’s sample should be evaluated and interpreted by a specialist in biochemistry by selecting the appropriate interference detection method.
- 7 February 2023
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 83 (2) , 125-132
Presence of macroproteins on the measurement of vitamin B12: studying high vitamin B12 levels using polyethylene glycol and heterophile antibody blocking tubes
Immune methods are measurement systems that can be affected by interference. The interfering substance may be endogenous immunoglobulins, antibodies, analyte-antibody complexes, and heterophile antibodies. In our study, we aimed to investigate the effect of macrovitamin B12 on high vitamin B12 levels measured using immune methods. Among the serum samples studied in our laboratory; serum from 145 individuals was determined as the patient group and serum from 50 individuals was determined as the control group. We investigated the effect of macroprotein on B12 measurement by using polyethylene glycol (PEG) precipitation, heterophile antibody blocking tube (HBT) and serial dilution methods. According to the recovery evaluation and the modified reference range evaluation after precipitation with PEG, the macrovitamin B12 percentage in the patient group was 58 (40%) and 65 (44.8%), respectively. There was no decrease in vitamin B12 values after the study with HBT. A lack of linearity was observed in 23 (18.7%) of 123 sera with serial dilution method. Macrovitamin B12 should be considered as a differential diagnosis of unexpectedly high vitamin B12 levels. According to the results of our study, we think that it would be appropriate to precipitate with PEG first when there is a suspicion of macrovitamin B12. In collaboration with clinical and laboratory, we recommend that the patient’s clinical status and additional laboratory findings be examined, and the patient’s sample should be evaluated and interpreted by a specialist in biochemistry by selecting the appropriate interference detection method.
- Open Access
- 31 January 2023
- Published by Adnan Menderes University in Adnan Menderes Üniversitesi Sağlık Bilimleri Fakültesi Dergisi
- Vol. 7 (1) , 208-216
Laboratory Tests to Distinguish COVID-19 Intensive Care Patients
Objective: The need for intensive care units has increased in the COVID-19 pandemic, and in this process, laboratory parameters are important. We aimed to evaluate the admission symptoms retrospectively, comorbid diseases, mean age, and laboratory data of RT-PCR(+) 60 service and 26 intensive care COVID-19 patients, to reveal the clinical and laboratory characteristics of the patients and to define the parameters that will help us about the prognosis.. Methods: We divided 86 COVID-19 RT-PCR (+) patients treated in our hospital into two groups as inpatients and intensive care patients. We compared symptom, comorbid disease and laboratory data in these patient groups and compared laboratory data statistically. Results: In our study, while the mean age of intensive care patients was 64, it was 58 in service patients. Comorbid diseases were found in 73% of intensive care patients and 51.6% in service patients. Hypertension (43%) and diabetes mellitus (22%) are the most common comorbid diseases in both groups. In addition, while neutrophil [(6.11(1.18-19.7) vs. 3.83(1.51-12.07) 109 /L, p=0.007], N/L ratio [5.74 (1.34-28.86) vs. 2.11 (0.64-9.14), p<0.001], D-dimer [ 482 (52-2522) vs. 249 (59-3561) µg/L, p=0.001], CRP [91.8 (0.49-331.7) vs. 14 (0-161) mg/L, p< 0.001], and procalcitonin [0.19 (0-6.94) vs. 0.04 (0-0.86) µg/L, p< 0.001] values were found to be significantly higher in intensive care patients, lymphocyte values [(1.12±0.54 ) vs. ( 1.81±0.90) 109 /L, p<0.001] were found to be significantly lower. Conclusion: COVID-19 is still affecting our world, and patients need intensive care. Lymphopenia, increase in neutrophil level, N/L ratio, D-dimer, CRP and procalcitonin levels are remarkable in intensive care patients.
- 31 January 2023
- Published by Adnan Menderes University in Adnan Menderes Üniversitesi Sağlık Bilimleri Fakültesi Dergisi
- Vol. 7 (1) , 208-216
Open AccessLaboratory Tests to Distinguish COVID-19 Intensive Care Patients
Objective: The need for intensive care units has increased in the COVID-19 pandemic, and in this process, laboratory parameters are important. We aimed to evaluate the admission symptoms retrospectively, comorbid diseases, mean age, and laboratory data of RT-PCR(+) 60 service and 26 intensive care COVID-19 patients, to reveal the clinical and laboratory characteristics of the patients and to define the parameters that will help us about the prognosis.. Methods: We divided 86 COVID-19 RT-PCR (+) patients treated in our hospital into two groups as inpatients and intensive care patients. We compared symptom, comorbid disease and laboratory data in these patient groups and compared laboratory data statistically. Results: In our study, while the mean age of intensive care patients was 64, it was 58 in service patients. Comorbid diseases were found in 73% of intensive care patients and 51.6% in service patients. Hypertension (43%) and diabetes mellitus (22%) are the most common comorbid diseases in both groups. In addition, while neutrophil [(6.11(1.18-19.7) vs. 3.83(1.51-12.07) 109 /L, p=0.007], N/L ratio [5.74 (1.34-28.86) vs. 2.11 (0.64-9.14), p<0.001], D-dimer [ 482 (52-2522) vs. 249 (59-3561) µg/L, p=0.001], CRP [91.8 (0.49-331.7) vs. 14 (0-161) mg/L, p< 0.001], and procalcitonin [0.19 (0-6.94) vs. 0.04 (0-0.86) µg/L, p< 0.001] values were found to be significantly higher in intensive care patients, lymphocyte values [(1.12±0.54 ) vs. ( 1.81±0.90) 109 /L, p<0.001] were found to be significantly lower. Conclusion: COVID-19 is still affecting our world, and patients need intensive care. Lymphopenia, increase in neutrophil level, N/L ratio, D-dimer, CRP and procalcitonin levels are remarkable in intensive care patients.
- 29 December 2022
- Published by Caleo in Turkish Society of Clinical Biochemistry
- Vol. 20 (3) , 138-152
Yasadışı Madde Analizlerinde Preanalitik Evre
Uyuşturucu ve uyarıcı madde çalışmalarında, analiz evresinin güvenliği ve doğruluğu yanında, preanalitik evrenin de laboratuvar uzmanı tarafından kontrol altında tutulması oldukça önemlidir. Bu süreçte, analizi isteyen klinik birim ile iş birliği içinde olmak ve uygun şartları, iş akışlarını birlikte planlamak en uygun yöntem olacaktır. Preanalitik evre; uygun numunenin belirlenmesi, test panelinin doğru olarak yapılandırılması, bilgi işlem sistemi ile ilgili düzenlemeler, numunelerin kimliklendirilmesi, gözetim altında örnek alınabilmesi için gerekli fiziksel düzenlemelerin kontrolü, olası hile yöntemlerinin önlenebilmesi için tedbir alınmasının sağlanması, hasta onamının alınması, numunenin güvenli transferi, örnek teslim alma ve kayıt sürecinin yapılandırılması, analiz öncesinde örneklerin güvenli saklanması süreçlerinin tamamını içermektedir.
- 29 December 2022
- Published by Caleo in Turkish Society of Clinical Biochemistry
- Vol. 20 (3) , 138-152
Yasadışı Madde Analizlerinde Preanalitik Evre
Uyuşturucu ve uyarıcı madde çalışmalarında, analiz evresinin güvenliği ve doğruluğu yanında, preanalitik evrenin de laboratuvar uzmanı tarafından kontrol altında tutulması oldukça önemlidir. Bu süreçte, analizi isteyen klinik birim ile iş birliği içinde olmak ve uygun şartları, iş akışlarını birlikte planlamak en uygun yöntem olacaktır. Preanalitik evre; uygun numunenin belirlenmesi, test panelinin doğru olarak yapılandırılması, bilgi işlem sistemi ile ilgili düzenlemeler, numunelerin kimliklendirilmesi, gözetim altında örnek alınabilmesi için gerekli fiziksel düzenlemelerin kontrolü, olası hile yöntemlerinin önlenebilmesi için tedbir alınmasının sağlanması, hasta onamının alınması, numunenin güvenli transferi, örnek teslim alma ve kayıt sürecinin yapılandırılması, analiz öncesinde örneklerin güvenli saklanması süreçlerinin tamamını içermektedir.
- 29 March 2022
- Published by Turkish Journal of Womens Health and Neonatology, University of Health Sciences in Türk Kadın Sağlığı ve Neonatoloji Dergisi
- Vol. 4 (1) , 1-7
İzmir İli Birinci ve İkinci Trimester Prenatal Tarama Testi Güncel Medyan Verilerinin Değerlendirilmesi
Amaç: Bu çalışmada, laboratuvarımızda yapılan prenatal tarama testlerinin güncel medyan değerlerinin hesaplanması ve risk hesaplamada kullandığımız paket programdaki medyan değerler ile karşılaştırılması hedeflenmiştir. Gereç ve Yöntem: Mayıs 2019-Mayıs 2020 tarihleri arasında İzmir ili ve çevresinden hastanemize yapılan başvurular sonucu 3264 birinci trimester tarama testi, 954 ikinci trimester tarama testi retrospektif olarak incelendi. Tüm parametreler İzmir Katip Çelebi Üniversitesi Atatürk Eğitim Araştırma Hastanesi Tıbbi Biyokimya Laboratuvarı’nda maternal serumdan çalışıldı. Elde edilen verilerin gebelik haftalarına göre güncel medyan değerleri ve medyan katları hesaplandı. Prisca paket programındaki medyan değerler ile istatistiksel olarak karşılaştırıldı. Bulgular: Güncel medyan değerlerinin; tüm haftalarda birinci trimester tarama testinde kullanılan free β-hCG için düşük, PAPP-A için yüksek olduğu, ikinci trimester tarama testinde kullanılan total β-hCG için 19. hafta dışında düşük olduğu görüldü (p
- 29 March 2022
- Published by Turkish Journal of Womens Health and Neonatology, University of Health Sciences in Türk Kadın Sağlığı ve Neonatoloji Dergisi
- Vol. 4 (1) , 1-7
İzmir İli Birinci ve İkinci Trimester Prenatal Tarama Testi Güncel Medyan Verilerinin Değerlendirilmesi
Amaç: Bu çalışmada, laboratuvarımızda yapılan prenatal tarama testlerinin güncel medyan değerlerinin hesaplanması ve risk hesaplamada kullandığımız paket programdaki medyan değerler ile karşılaştırılması hedeflenmiştir. Gereç ve Yöntem: Mayıs 2019-Mayıs 2020 tarihleri arasında İzmir ili ve çevresinden hastanemize yapılan başvurular sonucu 3264 birinci trimester tarama testi, 954 ikinci trimester tarama testi retrospektif olarak incelendi. Tüm parametreler İzmir Katip Çelebi Üniversitesi Atatürk Eğitim Araştırma Hastanesi Tıbbi Biyokimya Laboratuvarı’nda maternal serumdan çalışıldı. Elde edilen verilerin gebelik haftalarına göre güncel medyan değerleri ve medyan katları hesaplandı. Prisca paket programındaki medyan değerler ile istatistiksel olarak karşılaştırıldı. Bulgular: Güncel medyan değerlerinin; tüm haftalarda birinci trimester tarama testinde kullanılan free β-hCG için düşük, PAPP-A için yüksek olduğu, ikinci trimester tarama testinde kullanılan total β-hCG için 19. hafta dışında düşük olduğu görüldü (p
- 1 January 2022
- Published by Kare Publishing in Eurasian Journal of Medical Advances
- Vol. 2 (4) , 173-180
Relevancy of Serum SuPAR, PAI-1, MMP-9 Level, and Prognosis of Metastatic Colorectal Cancer During Diagnosis
Objectives: Serum suPAR, PAI-1, and MMP-9 biomarkers have been associated with the progression of the disease in many cancers, including the CRC. It aimed to determine the relation of serum suPAR, PAI-1, and MMP-9 levels with the prognosis of the disease in patients with mCRC. Methods: Nonmetastatic CRC patients who had not yet been treated with the oncology polyclinic in İKCU and blood samples were taken from the patients with metastatic CRC before and after treatment, and the obtained serum was preserved. PAI-1, suPAR, and MMP-9 levels were studied by ELISA. The results were used to establish the relation with prognosis. Results: When the metastatic CRC and non-metastatic CRC were compared before treatment for biomarkers; PAI-1(p-value: 0.030), suPAR(p-value: 0.009) and MMP-9(p-value: 0.003) were found to be highly significant. PAI-1 (p-value: 0.003), suPAR (p-value: 0.007), and MMP-9 (p-value: 0.001) in the pretreatment metastatic group and the control group after the treatment were statistically significant. ROC was performed and cut-off values were determined as (pai: 71.4 ng/ ml; supar: 1.97 ng/ ml; mmp: 812.5 ng/ ml). PFS and OS were evaluated to the cut-offs of markers using the Kaplan-Meier method. Cut off values were significant in terms of PFS (pai p-value, 0.008; supar p-value 0.019, mmp p-value 0.017) and OS (pai p-value, 0.03; supar p-value 0.059, mmp p-value 0.081). Conclusion: Serum PAI-1, suPAR, and MMP-9 levels reveal the prognosis of patients with metastatic CRC.
- 1 January 2022
- Published by Kare Publishing in Eurasian Journal of Medical Advances
- Vol. 2 (4) , 173-180
Relevancy of Serum SuPAR, PAI-1, MMP-9 Level, and Prognosis of Metastatic Colorectal Cancer During Diagnosis
Objectives: Serum suPAR, PAI-1, and MMP-9 biomarkers have been associated with the progression of the disease in many cancers, including the CRC. It aimed to determine the relation of serum suPAR, PAI-1, and MMP-9 levels with the prognosis of the disease in patients with mCRC. Methods: Nonmetastatic CRC patients who had not yet been treated with the oncology polyclinic in İKCU and blood samples were taken from the patients with metastatic CRC before and after treatment, and the obtained serum was preserved. PAI-1, suPAR, and MMP-9 levels were studied by ELISA. The results were used to establish the relation with prognosis. Results: When the metastatic CRC and non-metastatic CRC were compared before treatment for biomarkers; PAI-1(p-value: 0.030), suPAR(p-value: 0.009) and MMP-9(p-value: 0.003) were found to be highly significant. PAI-1 (p-value: 0.003), suPAR (p-value: 0.007), and MMP-9 (p-value: 0.001) in the pretreatment metastatic group and the control group after the treatment were statistically significant. ROC was performed and cut-off values were determined as (pai: 71.4 ng/ ml; supar: 1.97 ng/ ml; mmp: 812.5 ng/ ml). PFS and OS were evaluated to the cut-offs of markers using the Kaplan-Meier method. Cut off values were significant in terms of PFS (pai p-value, 0.008; supar p-value 0.019, mmp p-value 0.017) and OS (pai p-value, 0.03; supar p-value 0.059, mmp p-value 0.081). Conclusion: Serum PAI-1, suPAR, and MMP-9 levels reveal the prognosis of patients with metastatic CRC.
- 15 August 2020
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 31 (8) , 588-595
Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy
Background/Aims: Lipodystrophy is a rare metabolic disorder characterized by near total or partial lack of subcutaneous adipose tissue and associated with insulin resistance. We aimed to evaluate the efficacy of magnetic resonance spectroscopy imaging (MRS) to explore the fat content of the liver in patients with lipodystrophy and to determine the relationship between the liver fat accumulation and clinical presentations of lipodystrophy. Materials and Methods: Between July 2014 and February 2016, 34 patients with lipodystrophy were assessed by MRS for quantification of hepatic steatosis. All patients had metabolic abnormalities associated with insulin resistance. Metabolic parameters and the MRS findings were analyzed to identify potential correlations between the liver fat content and disease severity. Results: The MRS fat ratios (MRS-FR) were markedly higher, indicating severe hepatic steatosis in lipodystrophy. Patients with generalized and partial lipodystrophy had comparable levels of MRS-FRs, although patients with generalized lipodystrophy were significantly younger. Patients with genetically based lipodystrophy had elevated MRS-FR compared to those with acquired lipodystrophy (p=0.042). The MRS-FR was positively correlated with liver enzyme alanine aminotransferase (p=0.028) and serum adiponectin (p=0.043). Conclusion: Our data suggest that MRS might be an effective, noninvasive imaging method to quantify hepatic fat content in patients with lipodystrophy. Further studies are needed to validate the technique and threshold values which would allow accurate comparison of data acquired by different machines and centers.
- 15 August 2020
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 31 (8) , 588-595
Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy
Background/Aims: Lipodystrophy is a rare metabolic disorder characterized by near total or partial lack of subcutaneous adipose tissue and associated with insulin resistance. We aimed to evaluate the efficacy of magnetic resonance spectroscopy imaging (MRS) to explore the fat content of the liver in patients with lipodystrophy and to determine the relationship between the liver fat accumulation and clinical presentations of lipodystrophy. Materials and Methods: Between July 2014 and February 2016, 34 patients with lipodystrophy were assessed by MRS for quantification of hepatic steatosis. All patients had metabolic abnormalities associated with insulin resistance. Metabolic parameters and the MRS findings were analyzed to identify potential correlations between the liver fat content and disease severity. Results: The MRS fat ratios (MRS-FR) were markedly higher, indicating severe hepatic steatosis in lipodystrophy. Patients with generalized and partial lipodystrophy had comparable levels of MRS-FRs, although patients with generalized lipodystrophy were significantly younger. Patients with genetically based lipodystrophy had elevated MRS-FR compared to those with acquired lipodystrophy (p=0.042). The MRS-FR was positively correlated with liver enzyme alanine aminotransferase (p=0.028) and serum adiponectin (p=0.043). Conclusion: Our data suggest that MRS might be an effective, noninvasive imaging method to quantify hepatic fat content in patients with lipodystrophy. Further studies are needed to validate the technique and threshold values which would allow accurate comparison of data acquired by different machines and centers.